-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-08-30
The reference study used a drug screen to identify receptor tyrosine kinase and PDGFR inhibitors that preferentially affect ATRX-deficient high-grade glioma cells. Its combination experiments further showed that pairing these inhibitors with temozolomide produced pronounced toxicity, supporting ATRX status as a potentially useful biomarker for treatment-response interpretation.
-
Rucaparib and Spliceosome-Linked DNA Repair
2026-08-29
Rucaparib and AG-014699 provide a mechanistically rich platform for studying PARP1 inhibition, persistent DNA damage, and cancer-cell repair states. This article connects prostate cancer radiosensitization with emerging SmD2-dependent spliceosome biology in hepatocellular carcinoma to improve assay interpretation.
-
NET-DNA–CCDC25 Control of ILC3 Repair in Colitis
2026-08-28
This 2026 FASEB Journal study identifies a mechanistic pathway linking neutrophil extracellular trap DNA to impaired intestinal epithelial repair in ulcerative colitis. Its findings implicate CCDC25-dependent suppression of ILC3-derived IL-22, connecting extracellular DNA accumulation with reduced mucus, tight-junction integrity, and epithelial regeneration.
-
Dual-Action Inhibitors Reprogram p38α Dephosphorylation
2026-08-28
The 2024 bioRxiv preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can shift its activation-loop conformation to accelerate WIP1-catalyzed dephosphorylation. Its biochemical, kinetic, and X-ray structural evidence suggests a route to kinase inhibitors that combine immediate activity blockade with phosphatase-assisted signal shutdown, while leaving compound-specific translation to be tested.
-
Pam3CSK4: TLR1/2 Assays and Reflex Inflammation
2026-08-27
Build cleaner innate-immune experiments with Pam3CSK4, a defined TLR1/2 agonist for macrophage, platelet, and allergic inflammation workflows. Pair receptor-level stimulation with the neural controls highlighted by recent TRPV1 research to distinguish direct immune signaling from somato-autonomic regulation.
-
Berberine Hydrochloride: Gut–Bone Research Workflows
2026-08-27
Build reproducible metabolic, microbiome, organoid, and osteoimmune assays with Berberine hydrochloride rather than treating it as a single-endpoint reagent. This workflow translates tuft-cell and gut–bone findings into practical controls, solvent strategies, and troubleshooting decisions while preserving clear boundaries between preclinical evidence and therapeutic claims.
-
Hoechst 33342/PI Double Staining Kit Guide
2026-08-26
The Hoechst 33342/PI Double Staining Kit provides a two-color fluorescence workflow for distinguishing nuclear chromatin changes from loss of cell membrane integrity in cultured cells. It is intended for research use only; it should not be used as a standalone diagnostic test or as definitive proof of a specific cell-death mechanism.
-
L-Alanyl-L-Glutamine (B8228): Lab Guide
2026-08-26
This guide explains how to use L-Alanyl-L-Glutamine as a water-soluble L-Ala-L-Gln dipeptide for gastrointestinal, nutritional, and aqueous research workflows. It is suitable where glutamine delivery and solution handling are important, but it should not be selected for DMSO- or ethanol-based protocols or long-term storage of prepared solutions.
-
Fluo-4 AM for Podocyte Calcium Assays
2026-08-25
Fluo-4 AM converts transient Ca2+ flux into a practical live-cell readout for podocyte biology, receptor trafficking, and diabetic nephropathy research. This workflow combines sensitive fluorescence imaging with experimental controls that help distinguish calcium signaling from dye-loading or cell-health artifacts.
-
N4-Acetylcytidine: A Smarter Assay Strategy
2026-08-25
N4-Acetylcytidine is more than an RNA modification standard: it is a chemically defined probe for separating free-nucleoside metabolism from RNA-bound ac4C biology. This guide translates recent ASCH-domain structural findings into practical assay-selection, handling, and interpretation strategies.
-
LRRC8A–Caveolin-1 Signaling in PDAC Growth
2026-08-24
The reference study identifies a cholesterol-dependent LRRC8A–Caveolin-1 axis that links cell-volume regulation to KRAS/EGFR signaling, ribosome biogenesis, and biosynthetic growth in pancreatic ductal adenocarcinoma. Its integrated genetic, pharmacological, organoid, xenograft, and proteomic experiments position membrane organization as a mechanistic determinant of tumor-cell expansion and a potential vulnerability.
-
AZD1390 and G4 Stress in ATM Research
2026-08-24
Explore how AZD1390, a selective ATM kinase inhibitor, can separate DNA damage signaling from G-quadruplex replication stress. This article translates REV1–DHX36 findings into a rigorous assay framework for radiosensitization and cancer research.
-
CD36 Lipid Signaling Drives Immune Escape in AML
2026-08-23
A 2024 Cell Reports Medicine study identifies a non-canonical CD36 lipid-sensing program that enables AML cells to suppress T-cell activity and resist decitabine. The work connects OxLDL and palmitate uptake to TLR4-LYN-MYD88-NF-κB signaling and shows that statin-mediated lipid restriction can improve decitabine responses in preclinical models.
-
Phenytoin for Dynamic Myelin Damage Assays
2026-08-22
Phenytoin can help dissect how sodium-channel-dependent excitability influences early myelin damage. This assay-focused guide translates longitudinal myelin imaging findings into practical electrophysiology, dosing, timing, and interpretation decisions.
-
IWP-L6: A Functional Wnt Signaling Research Map
2026-08-22
IWP-L6 is a sub-nanomolar Porcupine inhibitor for dissecting Wnt signaling modulation across developmental and metabolic assays. This guide connects upstream Porcn enzyme inhibition with assay timing, branching morphogenesis, regeneration, and Wnt-driven osteoblast metabolism.